Earnest Partners LLC Catalent, Inc. Transaction History

Earnest Partners LLC

$22.1 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$42.56 - $59.82 $37.8 Million - $53.2 Million	-888,499 Reduced 79.63%	227,264 $12.8 Million
Q4 2023 Feb 14, 2024	SELL	$32.18 - $46.57 $1.13 Million - $1.64 Million	-35,116 Reduced 3.05%	1,115,763 $50.1 Million
Q3 2023 Nov 14, 2023	BUY	$44.2 - $50.2 $9.59 Million - $10.9 Million	216,870 Added 23.22%	1,150,879 $52.4 Million
Q2 2023 Aug 07, 2023	SELL	$31.86 - $67.26 $23.2 Million - $49 Million	-728,688 Reduced 43.83%	934,009 $40.5 Million
Q1 2023 May 15, 2023	SELL	$45.44 - $74.26 $46.5 Million - $75.9 Million	-1,022,439 Reduced 38.08%	1,662,697 $109 Million
Q4 2022 Feb 14, 2023	BUY	$41.39 - $81.0 $18.4 Million - $36.1 Million	445,745 Added 19.9%	2,685,136 $121 Million
Q3 2022 Nov 14, 2022	BUY	$72.36 - $113.1 $3.35 Million - $5.24 Million	46,349 Added 2.11%	2,239,391 $162 Million
Q2 2022 Aug 12, 2022	BUY	$87.2 - $114.05 $23.2 Million - $30.4 Million	266,601 Added 13.84%	2,193,042 $235 Million
Q1 2022 May 16, 2022	SELL	$94.19 - $124.49 $5.03 Million - $6.65 Million	-53,429 Reduced 2.7%	1,926,441 $214 Million
Q4 2021 Feb 07, 2022	SELL	$119.57 - $139.07 $67.5 Million - $78.6 Million	-564,910 Reduced 22.2%	1,979,870 $253 Million
Q3 2021 Nov 15, 2021	SELL	$109.17 - $142.35 $5.2 Million - $6.78 Million	-47,615 Reduced 1.84%	2,544,780 $339 Million
Q2 2021 Aug 16, 2021	SELL	$100.34 - $115.69 $743,920 - $857,725	-7,414 Reduced 0.29%	2,592,395 $280 Million
Q1 2021 May 17, 2021	BUY	$101.51 - $125.27 $24.4 Million - $30.1 Million	239,889 Added 10.17%	2,599,809 $274 Million
Q4 2020 Feb 16, 2021	SELL	$85.88 - $105.36 $15.6 Million - $19.2 Million	-181,850 Reduced 7.15%	2,359,920 $246 Million
Q3 2020 Nov 16, 2020	SELL	$72.74 - $92.5 $2.05 Million - $2.61 Million	-28,205 Reduced 1.1%	2,541,770 $218 Million
Q2 2020 Aug 13, 2020	SELL	$48.02 - $79.04 $10.2 Million - $16.8 Million	-213,149 Reduced 7.66%	2,569,975 $188 Million
Q1 2020 May 14, 2020	BUY	$36.95 - $62.95 $2.73 Million - $4.66 Million	73,986 Added 2.73%	2,783,124 $145 Million
Q4 2019 Feb 07, 2020	BUY	$47.06 - $56.64 $8.41 Million - $10.1 Million	178,773 Added 7.07%	2,709,138 $153 Million
Q3 2019 Nov 14, 2019	SELL	$47.45 - $58.05 $255,565 - $312,657	-5,386 Reduced 0.21%	2,530,365 $121 Million
Q2 2019 Aug 13, 2019	SELL	$39.26 - $54.21 $7,812 - $10,787	-199 Reduced 0.01%	2,535,751 $137 Million
Q1 2019 May 15, 2019	BUY	$29.84 - $43.92 $1.26 Million - $1.85 Million	42,162 Added 1.69%	2,535,950 $103 Million
Q4 2018 Feb 14, 2019	SELL	$29.95 - $46.34 $1.81 Million - $2.81 Million	-60,539 Reduced 2.37%	2,493,788 $77.8 Million
Q3 2018 Nov 14, 2018	BUY	$40.12 - $45.55 $250,067 - $283,913	6,233 Added 0.24%	2,554,327 $116 Million
Q2 2018 Aug 13, 2018	BUY	$38.72 - $42.52 $295,356 - $324,342	7,628 Added 0.3%	2,548,094 $107 Million
Q1 2018 May 15, 2018	BUY	$39.4 - $47.39 $1.64 Million - $1.98 Million	41,692 Added 1.67%	2,540,466 $104 Million
Q4 2017 Feb 14, 2018	SELL	$37.27 - $43.02 $2.66 Million - $3.07 Million	-71,382 Reduced 2.78%	2,498,774 $103 Million
Q3 2017 Nov 14, 2017	BUY	$33.75 - $41.67 $427,005 - $527,208	12,652 Added 0.49%	2,570,156 $103 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,557,504	2,557,504 $89.8 Million

Others Institutions Holding CTLT

# of Institutions

344

Shares Held

137M

Call Options Held

571K

Put Options Held

2.03M

Black Rock Inc. New York, NY

15.4M
Shares

$975 Million
0.02% of portfolio
State Street Corp Boston, MA

7.45M
Shares

$473 Million
0.02% of portfolio
Capital World Investors Los Angeles, CA

6.4M
Shares

$406 Million
0.06% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

4.52M
Shares

$287 Million
0.14% of portfolio
Barclays PLC London, X0

4.28M
Shares

$272 Million
0.07% of portfolio

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Earnest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Earnest Partners LLC with notifications on news.

Account